Review
doi: 10.2217/fon-2016-0040.
Epub 2016 May 11.
The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials
Affiliations
- PMID: 27168416
- DOI: 10.2217/fon-2016-0040
Item in Clipboard
Review
The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials
Future Oncol.
2016 Sep.
No abstract available
Keywords: CheckMate 025; anti-PD-1; immune-checkpoint inhibitors; immunotherapy; kidney cancer; nivolumab; renal cell carcinoma; therapy.
Similar articles
-
Immune Checkpoint Therapy in Renal Cell Carcinoma.Cancer J. 2016 Mar-Apr;22(2):92-5. doi: 10.1097/PPO.0000000000000177. Cancer J. 2016. PMID: 27111903 Review.
-
Clinical use of checkpoint inhibition in kidney cancer.Clin Adv Hematol Oncol. 2016 Jun;14(6):427-9. Clin Adv Hematol Oncol. 2016. PMID: 27379812 Review. No abstract available.
-
Nivolumab: targeting PD-1 to bolster antitumor immunity.Future Oncol. 2015;11(9):1307-26. doi: 10.2217/fon.15.52. Epub 2015 Mar 23. Future Oncol. 2015. PMID: 25798726 Review.
-
Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.Clin Adv Hematol Oncol. 2014 Feb;12(2):90-9. Clin Adv Hematol Oncol. 2014. PMID: 24892254 Review.
-
[Immunotherapy of renal cell cancer].Magy Onkol. 2017 Jun 6;61(2):126-131. Epub 2017 Apr 23. Magy Onkol. 2017. PMID: 28585613 Review. Hungarian.
Cited by
-
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.World J Clin Oncol. 2017 Feb 10;8(1):37-53. doi: 10.5306/wjco.v8.i1.37. World J Clin Oncol. 2017. PMID: 28246584 Free PMC article. Review.
-
Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.Ther Adv Med Oncol. 2017 Oct;9(10):627-636. doi: 10.1177/1758834017724314. Epub 2017 Aug 2. Ther Adv Med Oncol. 2017. PMID: 28974985 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
